Bill
S 8545
Would add Gaucher disease to newborn screening, guiding confirmatory tests, parental notification, and linked follow-up care for affected newborns.
Overview
- Bill Number: S 8545
- Title: Relates to newborn screening for Gaucher disease
- Status: REFERRED TO RULES
- Introduced: October 24, 2025
- Primary sponsor: Sam Sutton
- Related (companion): A 9211
What the bill is about
- Based on the title, S 8545 aims to address newborn screening specifically for Gaucher disease. The exact statutory language, scope, and mechanisms are not provided in the available information, so the precise changes to law (e.g., adding Gaucher disease to the newborn screening panel, testing protocols, or reporting requirements) cannot be confirmed from the summary alone.
Key provisions (noting that text is not publicly provided)
- The bill’s core purpose appears to relate to Gaucher disease within the context of newborn screening programs.
- Potential areas the bill could address (typical for newborn screening legislation) may include:
- Requirements to screen newborns for Gaucher disease as part of the state’s universal or targeted screening panel.
- Procedures for confirmatory testing, diagnostic workflow, and clinical follow-up.
- Notification requirements to parents or guardians and provision of counseling.
- Data collection, reporting, and coordination with healthcare providers and treatment centers.
- Funding, implementation timelines, and responsibilities of state health agencies and laboratories.
- The exact definitions, thresholds, age of eligibility, and any exemptions are not specified in the available information.
Who would be affected
- Newborns and their families: if Gaucher screening is mandated or recommended, parents/guardians would be involved in testing, results communication, and subsequent care planning.
- State public health laboratories and newborn screening programs: potential changes to testing panels, workflow, and data reporting.
- Healthcare providers (pediatricians, geneticists, metabolic specialists): changes in follow-up protocols, confirmatory testing, and treatment linkage.
- Payers and insurers: potential implications for coverage of screening, confirmatory tests, and early treatment.
Procedural and timeline aspects
- Status indicates the bill has been referred to Rules, a committee stage up the legislative process. No specific enactment date is provided.
- Legislative actions recorded: both on 2025-10-24, the bill was referred to Rules (listed twice, suggesting parallel entries or a clerical duplication).
- Next steps typically include consideration by the Rules committee, potential amendments, floor votes, and alignment with the companion bill A 9211.
Notes
- This summary is based on limited public information (bill title, status, sponsor, and related companion). The full bill text is needed to detail exact provisions, funding, timelines, and implementation requirements.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
